| abstract |
The invention discloses a C-Met inhibitor crystalline free base or a crystalline acid salt thereof, and a preparation method and application thereof. Specifically, the present invention discloses a C-Met/HGFR (hepatocyte growth factor receptor) kinase inhibitor crystal form 9-((8-fluoro-6-(1-methyl-1H-pyrazol-4-yl) )-[1,2,4]triazolo[4,3-a]pyridin-3-yl)thio)-4-methyl-2H-[1,4]oxadiazide [3,2 -c] quinoline-3(4H)-ketone free base or a crystalline acid salt thereof, and a process for the preparation and use thereof, wherein the crystalline free base is selected from the group consisting of free base crystal form I, and the powder X-ray diffraction pattern thereof comprises a peak at a diffraction angle (2 θ) of 13.0 ± 0.2°, 17.9 ± 0.2°, 21.2 ± 0.2°, and 31.4 ± 0.2°; a free base crystal form II having a powder X-ray diffraction pattern at 8.6 ± 0.2°, The peak at diffraction angle (2 θ) of 11.5±0.2°, 14.1±0.2° and 19.8±0.2°; the free base crystal form III, whose powder X-ray diffraction pattern is located at 12.8±0.2°, 14.8±0.2°, 18.0 The peak at the diffraction angle (2 θ) of ±0.2° and 20.5±0.2°; or the free base crystal form IV, the powder X-ray diffraction pattern of which is located at 8.9±0.2°, 12.6±0.2°, 17.0±0.2° and 17.9 A peak at a diffraction angle (2 θ) of ±0.2°. It can be used to prepare for the treatment of diseases associated with protein stimulationnDrugs, protein kinase inhibitors, anti-tumor drugs, etc., have broad application prospects. |